Short Interest in InterCure Ltd. (NASDAQ:INCR) Drops By 50.6%

Posted by Tristan Rich on Jan 18th, 2026

InterCure Ltd. (NASDAQ:INCR – Get Free Report) was the recipient of a significant drop in short interest in December. As of December 31st, there was short interest totaling 6,703 shares, a drop of 50.6% from the December 15th total of 13,558 shares. Based on an average daily volume of 190,443 shares, the short-interest ratio is currently 0.0 days. Based on an average daily volume of 190,443 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of InterCure in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Report on InterCure

InterCure Stock Up 1.0%

NASDAQ INCR traded up $0.01 on Friday, hitting $0.96. The stock had a trading volume of 31,779 shares, compared to its average volume of 171,085. The business’s fifty day moving average price is $1.22 and its 200 day moving average price is $1.43. The stock has a market cap of $43.75 million, a price-to-earnings ratio of 12.00 and a beta of 1.21. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.85 and a quick ratio of 1.09. InterCure has a 52-week low of $0.68 and a 52-week high of $1.78.

InterCure (NASDAQ:INCR – Get Free Report) last posted its quarterly earnings data on Wednesday, October 8th. The company reported ($0.02) earnings per share for the quarter. The firm had revenue of $19.25 million during the quarter.

InterCure Company Profile

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.